Regeneron's third quarter was marked by strong commercial execution and pipeline momentum, with the company delivering results that topped Wall Street’s revenue and profit expectations. Management credited growth to robust demand for its three core brands—DUPIXENT, EYLEA HD, and LIBTAYO—all of which hit new all-time sales highs. CEO Leonard Schleifer highlighted DUPIXENT’s continued leadership across multiple indications and cited EYLEA HD’s rapid adoption following recent label enhancements as key drivers. The company also benefited from its expanded collaboration with Sanofi and sustained momentum across existing and recent product launches.

Is now the time to buy REGN? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Regeneron’s Q3 earnings call

• Elizabeth Webster (Goldman Sachs) asked about CIDEB’s clinical differentiation; CSO George Yancopoulos emphasized the program’s genetic validation and the unprecedented liver fat reductions seen in early data.
• Brian Abrahams (RBC Capital Markets) inquired about pre-launch activities for cemdisiran; EVP Marion McCourt described the neurology team’s readiness but declined to share specifics, stating the team is "launch-ready."
• Akash Tewari (Jefferies) questioned the potential to expand the Sanofi alliance to include oral STAT6 inhibitors; CEO Leonard Schleifer said the alliance remains open to new opportunities but noted injectables with quarterly or semiannual dosing may offer greater convenience and efficacy than daily pills.
• Gregory Renza (Truist Securities) asked about managing breadth versus depth as the company expands into new therapeutic areas; Schleifer and Yancopoulos said Regeneron’s experience across specialties and focus on differentiated products support effective execution, while acknowledging resource allocation remains a key consideration.
• Alexandria Hammond (Wolfe Research) pressed for expectations on patient switching in PNH with upcoming readouts; McCourt stated that while early data are promising, further clinical differentiation is needed before market impact can be assessed.

Catalysts in upcoming quarters

In the upcoming quarters, the StockStory team will be watching (1) the FDA decision and launch uptake for cemdisiran in generalized myasthenia gravis, (2) progress in pivotal trial initiations and interim data readouts for key pipeline programs like CIDEB and ubamatamab, and (3) market share trends and pricing dynamics within the EYLEA HD and LIBTAYO franchises. Execution in both established and emerging therapeutic areas remains a focus for tracking Regeneron’s long-term strategy.

Regeneron currently trades at $928, up from $818.77 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

The best stocks for high-quality investors

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.